Diffusion capacity and static hyperinflation as markers of disease progression predict 3‐year mortality in COPD : Results from COSYCONET
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background and Objective Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV 1 , SGRQ, exacerbation history) and associated with unique baseline biomarker profiles. We explored 18‐month measures of disease progression associated with 18–54‐month mortality, including changes in hyperinflation parameters and transfer factor, in a large German COPD cohort. Methods Analysing data of 1364 patients from the German observational COSYCONET‐cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models. Results Increased risk of 18–54‐month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV 1 (20 mL increments), increase in RV/TLC (2% increments) and SGRQ (≥6 points), and an exacerbation grade of 2 at 18 months. Decrease in KCO % predicted ≥7.5% and an increase of RV/TLC ≥2% were the most frequent measures of 18‐month disease progression occurring in ~52% and ~46% of patients, respectively. IL‐6 and CRP thresholds exhibited significant associations with medium‐ and long‐term disease measures. Conclusion In a multicentric cohort of COPD, new markers of current disease activity predicted mid‐term mortality and could not be anticipated by baseline biomarkers. image
Source: Respirology
DOI: 10.1111/resp.14843
Authors: Hendrik Pott, Barbara Weckler, Swetlana Gaffron, Roman Martin, Dieter Maier, Peter Alter, Frank Biertz, Tim Speicher, Wilhelm Bertrams, Anna Lena Jung, Katrin Laakmann, Dominik Heider, Miel Wouters, Claus F. Vogelmeier, Bernd Schmeck, the COSYCONET Study Group
Institutions: Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, Heinrich Heine University Düsseldorf, Labvantage - Biomax GmbH (Germany), German Center for Lung Research, Medizinische Hochschule Hannover, Universities of Giessen and Marburg Lung Center, University of Münster, Sigmund Freud Privatuniversität Wien, Maastricht University Medical Centre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,330
Awards: G1583474049, G2141234337, G2442196147, G3455431222, G3673810263, G4472029391, ERACoSysMed2 - Verbundprojekt: SysMed-COPD - Entwicklung eines systemmedizinbasierten Entscheidungsunterstützungssystems für die Therapie der COPD - Deutsches Teilprojekt, Kompetenznetz Asthma/COPD Verbundprojekt: COPD und systemische Konsequenzen/Komorbiditäten, Teilprojekte 1, 4, 12 und Infrastruktur für das Kompetenznetz, G569136689, PerMed-COPD - Personalisierte Medizin für die Prävention und Behandlung von COPD - Prospektive klinische Studie und Molekulare Biomarker, G8740723945, G96128947
OpenAlex ID: W4403714644
